Result of Annual General Meeting

BiVictriX Therapeutics PLC

24 July 2024

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

Result of Annual General Meeting

Alderley Park, 24 July 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next  generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, announces that at the Company's Annual General Meeting held today at 3:00 pm at the Company's registered office, Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG, all resolutions were duly passed.

Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 25^th June 2024.

Details of proxy votes received prior to the meeting will be made available on the Company's website at https://bivictrix.com/investor-relations/. 

The proxy results were as follows:

RESOLUTION NUMBER	VOTES FOR	VOTES AGAINST	VOTES WITHELD	TOTAL VOTES
1	10,739,609	0	0	10,739,609
2	10,739,609	0	0	10,739,609
2	10,057,109	682,500	0	10,739,609
4	10,057,109	682,500	0	10,739,609
5	10,064,609	675,000	0	10,739,609
6	10,064,609	675,000	0	10,739,609

ENDS For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Michael Kauffman, Non-Executive Chairman Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker)   Tel: [phone] David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Liberum Limited (Joint Broker)   Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl ICR Consilium Mary-Jane Elliott, Namrata Taak, Max Bennett, Emmalee Hoppe Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com  

 

END